Review of Neuropathic Pain Screening and Assessment Tools

  • R. Carter W. JonesIII
  • Miroslav “Misha” Backonja
Neuropathic Pain (E Eisenberg, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neuropathic Pain


Chronic pain due to injury to or diseases of the nervous system, known as neuropathic pain (NP), is a common debilitating medication condition for which there are currently several symptomatically effective therapies. Therefore, early identification of NP in the primary and specialty care setting will avoid unnecessary delays in amelioration of symptoms. Given that it is associated with unique symptoms and physical exam signs, several assessment tools have been developed to aid medical practitioners in the identification of patients with NP. The majority of these tools have been developed to differentiate NP from nonNP and to quantify the severity of symptoms that define NP, and some have been used to aid in assessment of response to interventions. This focused review will describe the primary NP assessment tools that are currently available, and discuss their suitability for screening patients and for research applications. Wider use of NP assessment tools will facilitate the development of new therapies, further clarify the epidemiology of this condition, and improve the treatment of NP.


Neuropathic pain Assessment Screening LANSS NPS NPSI StEP DN-4 NPQ ID pain painDETECT SF-MPQ-2 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–5.PubMedCrossRefGoogle Scholar
  2. 2.
    • Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147–57. This is the first published assessment tool with the purpose of discriminating NP from nonNP, though a few others were developed at approximately same time.PubMedCrossRefGoogle Scholar
  3. 3.
    Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005;6:149–58.PubMedGoogle Scholar
  4. 4.
    Li J, Feng Y, Han J, Fan B, Wu D, Zhang D, et al. Linguistic adaptation, validation and comparison of 3 routinely used neuropathic pain questionnaires. Pain Physician. 2012;15:179–86.PubMedGoogle Scholar
  5. 5.
    Unal-Cevik I, Sarioglu-Ay S, Evcik D. A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4. J Pain. 2010;11:1129–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Gürsoy AE, Kolukısa M, Yıldız GB. Relationship between electrodiagnostic severity and neuropathic pain assessed by the LANSS pain scale in carpal tunnel syndrome. Neuropsychiatr DisTreat. 2013;9:65–71.CrossRefGoogle Scholar
  7. 7.
    Türkyılmaz AK, Kurt EE, Çapkın E, Karkucak M. Assessment of Neuropathic Pain in Patients with Fibromyalgia Syndrome: A Pilot Study. J Muscoskeletal Pain Informa Healthcare New York, USA. 2012;20:170–6.CrossRefGoogle Scholar
  8. 8.
    Burgess PR, Perl ER. Myelinated afferent fibres responding specifically to noxious stimulation of the skin. J Physiol (Lond). 1967;190:541–62.Google Scholar
  9. 9.
    Krause SJ, Backonja M-M. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19:306–14.PubMedCrossRefGoogle Scholar
  10. 10.
    •• Backonja M-M, Krause SJ. Neuropathic pain questionnaire—short form. Clin J Pain. 2003;19:315–6. Shortest three-questions tool that is still able to provide differentiation between NP and nonNP.PubMedCrossRefGoogle Scholar
  11. 11.
    Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29–36.PubMedCrossRefGoogle Scholar
  12. 12.
    Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, et al. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. J Int Med Res. 2011;39:366–77.PubMedCrossRefGoogle Scholar
  13. 13.
    de Moraes Vieira EB, Garcia JBS, da Silva AAM, Mualem Araujo RLT, Jansen RCS. Prevalence, characteristics, and factors associated with chronic pain with and without neuropathic characteristics in Sao Luis. Brazil J Pain Symptom Manage. 2012;44:239–51.CrossRefGoogle Scholar
  14. 14.
    Lekpa FK, Ndongo S, Ka O, Zeba D, Compaore C, Pouye A, et al. Socio-demographic and clinical profile of chronic pain with neuropathic characteristics in sub-Saharan African elderly. Eur J Pain 17: 939–43.Google Scholar
  15. 15.
    • Truini A, Padua L, Biasiotta A, Caliandro P, Pazzaglia C, Galeotti F, et al. Differential involvement of A-delta and A-beta fibres in neuropathic pain related to carpal tunnel syndrome. Pain. 2009;145:105–9. This is a particularly interesting study demonstrating correlation of symptom description in neuropathic pain with abnormalities in the function of specific types of peripheral afferent neuronal fibers.PubMedCrossRefGoogle Scholar
  16. 16.
    Correa-Illanes G, Roa R, Piñeros JL, Calderón W. Use of 5 % lidocaine medicated plaster to treat localized neuropathic pain secondary to traumatic injury of peripheral nerves. Local Reg Anesth. 2012;5:47–53.PubMedGoogle Scholar
  17. 17.
    Sadler A, Wilson J, Colvin L. Acute and Chronic Neuropathic Pain in the. Use of Screening Tools. Clin J Pain.: Hospital Setting; 2012.Google Scholar
  18. 18.
    Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Rados I, Sakic Zdravcevic K, Hrgovic Z. painDETECT questionnaire and lumbar epidural steroid injection for chronic radiculopathy. Eur Neurol. 2013;69:27–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Reyes-Gibby C, Morrow PK, Bennett MI, Jensen MP, Shete S. Neuropathic pain in breast cancer survivors: using the ID pain as a screening tool. J Pain Symptom Manage. 2010;39:882–9.PubMedCrossRefGoogle Scholar
  21. 21.
    • Scholz J, Mannion RJ, Hord DE, Griffin RS, Rawal B, Zheng H, et al. (2009) A Novel Tool for the Assessment of Pain: Validation in Low Back Pain. Rice A, editor. PLoS Med 6: e1000047. This paper describes the development of the StEP assessment tool, which has the highest reported sensitivity and specificity, even greater than MRI imaging, for the identification neuropathic low back pain. It also has the most involved physical exam components, and consequently likely requires the most time to perform of any of the tools.Google Scholar
  22. 22.
    •• Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332–8. This is the first published tool designed to assess the severity of NP symptoms.PubMedCrossRefGoogle Scholar
  23. 23.
    Fishbain DA, Lewis JE, Cutler R, Cole B, Rosomoff HL, Rosomoff RS. Can the neuropathic pain scale discriminate between non-neuropathic and neuropathic pain? Pain Med. 2008;9:149–60.PubMedCrossRefGoogle Scholar
  24. 24.
    Hartrick CT, Kovan JP, Naismith P. Outcome prediction following sympathetic block for complex regional pain syndrome. Pain Pract. 2004;4:222–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5 % effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain. 2002;18:297–301.PubMedCrossRefGoogle Scholar
  26. 26.
    Tai Q, Kirshblum S, Chen B, Millis S, Johnston M, DeLisa JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25:100–5.PubMedGoogle Scholar
  27. 27.
    Jensen MP, Gammaitoni AR, Olaleye DO, Oleka N, Nalamachu SR, Galer BS. The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome. J Pain. 2006;7:823–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Rog DJ, Nurmikko TJ, Friede T, Young CA. Validation and reliability of the Neuropathic Pain Scale (NPS) in multiple sclerosis. Clin J Pain. 2007;23:473–81.PubMedCrossRefGoogle Scholar
  29. 29.
    Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248–57.PubMedCrossRefGoogle Scholar
  30. 30.
    Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. Efficacy and safety of 5 % lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009;29:231–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Moulin DE, Richarz U, Wallace M, Jacobs A, Thipphawong J. Efficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studies. J Pain Palliat Care Pharmacother. 2010;24:200–12.PubMedCrossRefGoogle Scholar
  32. 32.
    Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain. 2008;138:343–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Pazzaglia C, Vollono C, Ferraro D, Virdis D, Lupi V, Le Pera D, et al. Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: a laser-evoked potential study. Pain. 2010;149:379–85.PubMedCrossRefGoogle Scholar
  34. 34.
    Sommer C, Richter H, Rogausch JP, Frettloh J, Lungenhausen M, Maier C. A modified score to identify and discriminate neuropathic pain: a study on the German version of the Neuropathic Pain Symptom Inventory (NPSI). BMC Neurol. 2011;11:104.PubMedCrossRefGoogle Scholar
  35. 35.
    Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, et al. Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain. 2009;144:35–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Saldana MT, Perez C, Navarro A, Masramón X, Rejas J. Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice. Clin Drug Investig. 2012;32:401–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Gilron I, Tu D, Holden RR. Sensory and affective pain descriptors respond differentially to pharmacological interventions in neuropathic conditions. Clin J Pain. 2013;29:124–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-Over, Open-Label Trial of the Effects of Gabapentin versus Pregabalin on Painful Peripheral Neuropathy and Health-Related Quality of Life in Haemodialysis Patients. Clin Drug Investig. 2013;33:401–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Adelmanesh F, Jalali A, Attarian H, Farahani B, Ketabchi SM, Arvantaj A, et al. Reliability, validity, and sensitivity measures of expanded and revised version of the short-form McGill Pain Questionnaire (SF-MPQ-2) in Iranian patients with neuropathic and non-neuropathic pain. Pain Med. 2012;13:1631–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, et al. Using screening tools to identify neuropathic pain. Pain. 2007;127:199–203.PubMedCrossRefGoogle Scholar
  41. 41.
    Gilron I, Attal N, Bouhassira D, Dworkin RH (2010) Assessment of Neuropathic Pain. Turk DC, Melzack R, editors. Handbook of Pain Assessment. 3rd ed. The Guilford PressGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • R. Carter W. JonesIII
    • 1
  • Miroslav “Misha” Backonja
    • 2
    • 3
  1. 1.Center for Pain MedicineUC San DiegoSan DiegoUSA
  2. 2.Medical Director Neuroscience ResearchCRILifetree ResearchSalt Lake CityUSA
  3. 3.University of WisconsinMadisonUSA

Personalised recommendations